Molex company Phillips Medisize has announced a strategic investment to acquire the complete footprint of its Chippenham, UK site. Spanning nearly 59,000m2 on approximately 3.41 acres, the acquisition strengthens the company’s Global Inhalation Center of Excellence (COE). In addition, this features a dedicated facility in Cambridge.
The expansion follows the 2025 acquisition of Vectura Group Ltd. What’s more, it provides Phillips Medisize with long-term operational control to accelerate innovation, broaden combination product development. Also to scale clinical trial supplies manufacturing for a rapidly growing pharmaceutical pipeline.
Scaling Capacity for Complex Inhaled Therapies
The enhanced Chippenham footprint provides dedicated laboratories, advanced cleanroom capacity, and technical infrastructure. Therefore, the firm can better support global pharmaceutical customers from early-stage feasibility through commercial scale-up.
The facility supports major inhalation formats, including dry powder inhalers (DPIs) and nebulizers, alongside powder and liquid formulation expertise, advanced particle engineering via spray drying, and comprehensive analytical testing.
Charlie Schumacher, Vice President of Inhalation Therapies at Phillips Medisize, noted that the business is tracking ahead of schedule, saying: “With our inhalation revenue projected to grow substantially over the next five years, securing this full site ensures we have the dedicated talent, laboratories and cleanroom capacity required… This expansion in Chippenham reinforces our momentum and ensures proven technical expertise and manufacturing continuity for our customers worldwide.”
Sandy Munro, Chief Inhalation Scientist at Phillips Medisize, added: “Our team is absolutely delighted to be where we should be, back at industry conferences and on the podium sharing our latest research. We remain deeply committed to advancing the science in our field to bring more effective inhalation therapies to patients across the world, including those dealing with complex and challenging diseases like Pulmonary Arterial Hypertension (PAH).”
Key Takeaways for Growth Hub Readers
- Investing in Specialist Infrastructure: Securing long-term operational control of R&D and manufacturing facilities allows life sciences leaders to de-risk supply chains and capture surging global demand for outsourced drug delivery solutions.
- Capitalising on M&A Momentum: Effective integration following major acquisitions (such as Vectura Group) can accelerate time-to-market and drive robust multi-year revenue growth.
- Supporting High-Value Export Sectors: Advanced engineering and manufacturing hubs reinforce the UK’s position as a global leader in high-value medical technology and pharmaceutical development.
Shape the Future of Manufacturing and Industrial Strategy!
While major life sciences firms expand their operational footprints, understanding how industrial and manufacturing businesses adapt their commercial strategies remains vital.
How is your manufacturing enterprise balancing supply chain resilience, capital investment, and digital transformation? Help us establish the national benchmark for industrial commercial growth.
Take part in the 2027 Manufacturing Sales Survey!
By sharing your experience, you will directly inform The Growth Hub’s comprehensive annual benchmark for manufacturing and industrial commercial strategy.
Quick & Focused: Takes under five minutes to complete.
Exclusive Access: All contributors receive early access to the full benchmarking report upon publication.
👉 Click Here to Complete the 2027 Manufacturing Sales Survey Now
